Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy.
Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy.
Support Care Cancer. 2019 Sep;27(9):3531-3535. doi: 10.1007/s00520-019-4663-1. Epub 2019 Jan 26.
Antiemetics are being used both for the treatment and prophylaxis of opioid-induced nausea and vomiting (OINV) in clinical practice, despite the lack of evidence for the prophylactic benefit. Studies among Japanese physicians demonstrated over 80% prescribe antiemetics, with neuroleptic antipsychotics as the most commonly prescribed drugs. Our objective was to elucidate the current scenario of the prophylactic use of antiemetics for OINV among Italian physicians.
We conducted a web-based cross-sectional national survey. All the invited participants received an e-mail with an 11-item electronic questionnaire accessible through a direct link. Anonymity was guaranteed. According to the exploratory intent of the survey, we did not predefine any formal statistical hypothesis. Associations between variables were tested by the Pearson chi-square or the Fisher exact test.
From January to March 2017, 112 completed the electronic questionnaire (112/256, overall response rate, 43.7%). Nearly half of the participants were oncologists (54; 48.2%). Sixty-one (54.4%) physicians worked in palliative care units. About 45% of the interviewed prescribed prophylactic antiemetics at the beginning of opioid prescription. The most commonly chosen drugs for this purpose were prokinetics such as metoclopramide and domperidone (84%), followed by 5-HT3 antagonists (8%), neuroleptic antipsychotics (6%), and corticosteroids (2%). Ninety-one physicians (81%) declared to prescribe antiemetics at the occurrence of OINV, mainly prokinetics (N = 70; 77%).
Italian physicians do not commonly prescribe prophylactic antiemetics for OINV. Unlike previously reported data, dopamine antagonists resulted the most commonly prescribed drugs. Prospective clinical trials are necessary to evaluate the real efficacy of this practice.
尽管没有预防益处的证据,但在临床实践中,止吐药被用于治疗和预防阿片类药物引起的恶心和呕吐(OINV)。在日本医生的研究中,超过 80%的医生开止吐药,最常开的药物是神经安定型抗精神病药。我们的目的是阐明意大利医生目前对 OINV 预防性使用止吐药的情况。
我们进行了一项基于网络的全国性横断面调查。所有受邀参与者都收到了一封电子邮件,其中包含一个可通过直接链接访问的 11 项电子问卷。保证了匿名性。根据调查的探索性目的,我们没有预先定义任何正式的统计假设。通过 Pearson 卡方检验或 Fisher 精确检验测试变量之间的关联。
2017 年 1 月至 3 月,112 人完成了电子问卷(112/256,总应答率为 43.7%)。近一半的参与者是肿瘤学家(54 人;48.2%)。61 名(54.4%)医生在姑息治疗病房工作。约 45%的受访者在开阿片类药物处方时就预防性开具止吐药。为此目的最常选择的药物是促动力药,如甲氧氯普胺和多潘立酮(84%),其次是 5-HT3 拮抗剂(8%)、神经安定型抗精神病药(6%)和皮质类固醇(2%)。91 名医生(81%)在发生 OINV 时会开止吐药,主要是促动力药(N=70;77%)。
意大利医生通常不会为 OINV 预防性开具止吐药。与之前报道的数据不同,多巴胺拮抗剂是最常开的药物。需要前瞻性临床试验来评估这种做法的真正疗效。